NanO2 for Large Vessel Occlusion Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT05389748

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05389748
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05389748. Randomized; single masking; primary purpose treatment. Start 2023-04-01 (anticipated); primary completion 2025-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NanO2 for Large Vessel Occlusion Stroke
Acronym
PROVEN
Intervention (Other)
Placebo
Intervention (Biological)
dodecafluoropentane emulsion (DDFPe)
Lead sponsor
NuvOx LLC (class: industry)
Collaborator
University of Arkansas (class: other)
Collaborator
Stanford University (class: other)
Collaborator
Washington Regional Medical Center (class: other)

Record details

Record id
cardio:ct-nct05389748
Content hash
268e33d309929a4b9afc87f3ceaba708760c3d186d71608b94a194576b975948